On August 21, 2026, the trial registry listed an update for OBESIAL, a prospective interventional real-world study of a multidisciplinary obesity management programme. The study, registered under identifier NCT07779343, involves semaglutide, which is an approved compound. The trial's phase is listed as not applicable, reflecting its real-world observational and interventional design rather than a traditional clinical trial phase. Its current status is recruiting, meaning the study is actively enrolling participants as of the listed date.
No results have been posted for this trial at this time. The registry entry does not provide outcome data, efficacy findings, or safety conclusions. This brief reports only the trial's title, status, phase, and date as recorded in the registry.
Readers interested in the design or scope of the OBESIAL study can consult the official registry listing for further details on eligibility criteria, study locations, and objectives once available. Updates to recruitment status or the posting of results would be reflected in future registry entries.
For more background on semaglutide, including its approved uses and general profile, readers can refer to the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT07779343"]